URMC / Research / Clinical Trials / Study Details IBRS19182 / CAPItello-291 / Ajay DhakalResearch Question:What is the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with advanced breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy?Basic Study Information Purpose:Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy. Location: University of Rochester Medical CenterStudy Reference #: IBRS19182Lead Researcher (Principal Investigator) Lead Researcher: Ajay Dhakal Study Contact InformationStudy Coordinator: Amber JohnsonEmail: amber_johnson@urmc.rochester.edu Additional Study Details URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search